Publicité
Publicité

SNOA

SNOA logo

Sonoma Pharmaceuticals, Inc. Common Stock

3.67
USD
Sponsorisé
-0.10
-2.78%
09 janv., 15:58 UTC -5
Fermé
exchange

Après-marché

3.56

-0.11
-2.99%

SNOA Rapports sur les bénéfices

Ratio de surprise positive

SNOA a dépassé 11 des 21 dernières estimations.

52%

Prochain rapport

Date du prochain rapport
03 févr. 2026
Estimate for Q3 26 (Revenue/ EPS)
$4.41M
/
-$0.31
Variation implicite de Q2 26 (Revenue/ EPS)
-21.26%
/
-3.13%
Variation implicite de Q3 25 (Revenue/ EPS)
+23.81%
/
-50.79%

Sonoma Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 04 nov. 2025, SNOA reported earnings of -0.32 USD per share (EPS) for Q2 26, missing the estimate of -0.31 USD, resulting in a -1.20% surprise. Revenue reached 5.60 million, compared to an expected 4.35 million, with a 28.94% difference. The market reacted with a -0.53% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analystes forecast an EPS of -0.31 USD, with revenue projected to reach 4.41 million USD, implying an baisse of -3.13% EPS, and baisse of -21.26% in Revenue from the last quarter.
FAQ
For Q2 2026, Sonoma Pharmaceuticals, Inc. Common Stock reported EPS of -$0.32, missing estimates by -1.2%, and revenue of $5.60M, 28.94% above expectations.
The stock price moved down -0.53%, changed from $3.78 before the earnings release to $3.76 the day after.
The next earning report is scheduled for 03 févr. 2026.
Based on 3 analystes, Sonoma Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.31 and revenue of $4.41M for Q3 2026.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité